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Abstract
Background: Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while
results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term
impact is debated. We evaluated irAE reports related to high dose interleukin-2 therapy (IL-2) documented in the
PROCLAIMSM registry data base from 2008 to 2016 (NCT01415167, August 9, 2011).
Methods: Reports on 1535 patients, including 623 with metastatic melanoma (mM) and 919 with metastatic renal
cell cancer (mRCC) (7 patients had both diseases), were queried for irAEs. The timing of the event was categorized
as occurring before, during or after IL-2 or related to any checkpoint inhibitor (CPI). mM patients and mRCC
patients were analyzed separately. Tumor control [complete + partial response + stable disease (CR + PR + SD) was
compared between those experiencing no irAE versus those with the development of irAEs. Survival was analyzed
by tumor type related to timing of irAE and IL-2, and in those with or without exposure to CPI.
Results: Median follow-up was 3.5+ years (range 1–8+ years), 152 irAEs were reported in 130 patients (8.4% of all
PROCLAIMSM patients): 99 (16%) in mM and 53 (5.8%) in mRCC patients. 31 irAEs occurred prior to IL-2, 24 during
IL-2, and 97 after IL-2 therapy. 74 irAEs were attributed to IL-2 only (during/ after IL-2). Of the 97 post IL-2 irAEs, 24
were attributed to CPI, and 15 could not be distinguished as caused by IL-2 or CPI. Tumor control was 71% for
those experiencing irAE, and 56% for those with no irAE (p = 0.0008). Overall survival was significantly greater for
those experiencing irAEs during/ after IL-2 therapy, compared to those with no irAE or irAE before IL-2 therapy, in
mM patients, median 48 months vs 18 months (p < 0.0001), and in mRCC patients, median 60 months vs
40 months (p = 0.0302), independent of CPI-related irAEs. IL-2-related irAEs were primarily vitiligo and thyroid
dysfunction (70% of IL-2 related irAEs), with limited further impact.
Conclusions: irAEs following IL-2 therapy are associated with improved tumor control and overall survival. IrAEs
resulting from IL-2 and from CPIs are qualitatively different, and likely reflect different mechanisms of action of
immune activation and response.
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Background
Immune-related adverse events (irAEs) are associated with
immunotherapy for cancer. Data from the 1990’s reported
irAEs following treatment with interferon-α, vaccines, ac-
tivated lymphocytes, and interleukin-2 (IL-2), primarily in
the treatment of the identified immune responsive can-
cers, melanoma and renal cell carcinoma [1–5]. In that
early literature, the most common irAEs reported were
thyroid dysfunction, both hypothyroidism and hyperthy-
roidism, with the frequent development of anti-thyroid
antibodies [6–10]. Additional laboratory studies have de-
scribed activated intra-thyroid lymphocytes [11]. Clinical
observations have demonstrated frequent resolution of
thyroid dysfunction without replacement therapy after
completion of IL-2 treatment, although a number of pa-
tients do require thyroid replacement therapy, including
maintenance replacement. Early reports observed thyroid
dysfunction with immunotherapy in patients with either
metastatic melanoma (mM) or metastatic renal cell cancer
(mRCC), the most commonly treated tumor types. The
correlation of the development of thyroid dysfunction and
clinical outcome was controversial at that time [1–10].
The other most frequently reported irAE from IL-2 with
or without interferon, specific to patients with mM, is viti-
ligo, a depigmentation phenomenon that requires no
intervention. This has been associated with many types of
immunotherapy evaluated in mM, including vaccines,
interferon, IL-2, and adoptive cell transfer [12–15]. Rare
serious irAEs have been reported with cytokine therapy,
including IL-2, usually as case reports, and immune cell
infiltrations were described in affected organs in some
reports [16–19].
The acute toxicity noted with IL-2 administration has
primarily been attributed to the induced capillary leak
syndrome, as well as to effects of secondary cytokine re-
lease [20–27]. Early physiologic studies of IL-2 demon-
strated the interaction of activated mononuclear cells
with endothelium, causing leakage, and vascular accu-
mulation of leukocytes and platelets impairing perfusion
[20–23]. Also demonstrated were the effects of second-
ary cytokines on renal and hepatic function [24–27].
Clinically, the induced acute organ dysfunction (renal,
hepatic, pulmonary) was and is observed during IL-2 ad-
ministration and is rapidly reversible upon discontinu-
ation of IL-2 [20].
The development of immune checkpoint inhibitors
(CPIs) as anti-tumor therapeutic agents, directed at
cytotoxic T-lymphocyte-associated antigen-4 receptor
(CTLA-4) or programmed death receptor −1 (PD-1) or
its ligand (PD-L1) has demonstrated the frequent occur-
rence and a broader spectrum of treatment-related
irAEs. Some require acute therapeutic intervention and
some require long-term management [28–32]. Data sug-
gest the advent of irAEs may correlate with anti-tumor
clinical benefit, although this has not been consistently
seen [4, 7, 12, 14, 32, 33].
In Europe, IL-2 is administered at lower doses and for
prolonged courses, therefore longer exposure, and irAEs
are reported with these regimens as well [10]. Some have
postulated that those who do well on such therapy will
have longer exposure as the treatment continues, and
therefore be at more risk of developing irAEs, rather
than the irAE signaling better outcome [34]. However, a
recent meta-analysis makes a strong case that the devel-
opment of vitiligo following immunotherapy of any type
has a positive prognostic impact in mM [14]. With re-
gard to mRCC, reports are mixed, with some strongly
indicating a relationship between irAEs and activation of
the anti-tumor component of the immune response and
others reporting no correlation [4, 7, 9, 10].
Therefore, to provide a contemporary evaluation of IL-
2-related irAEs and clinical outcome, and to reflect
treatment with high dose IL-2, administered as a short
course, without maintenance, we searched the PRO-
CLAIMSM data-base (2006–2016), a registry study based
on treatment with high dose IL-2 (ProleukinR). We re-
port the spectrum of irAEs reported in the registry re-
lated to high dose IL-2, and evaluate their occurrence
with respect to disease response and overall survival.
Methods
Patients (Table 1)
The PROCLAIMSM registry is a data base study
(NCT01415167) collecting information on patients treated
with high dose IL-2 from 2006 and ongoing. The study was
approved by the investigational review boards of the sites
enrolling subjects and all patients provided written, in-
formed consent. The data reported herein reflects patients
treated from 2006 to 2016. As of the data cutoff, 1535 pa-
tients have been entered, including 426 accrued retrospect-
ively, and 1109 (72%) accrued prospectively. This report
Table 1 Patients 2006–2016 (n = 1535)a
Metastatic Melanoma (mM) 623 patients
62% male, 38% female
Median age, 53 years,
Range, 19–84 years
Metastatic Renal Cell Cancer (mRCC) 919 patients
72% male, 28% female
Median age, 57 years,
Range, 18–84 years
7 patients had both mM and mRCC – counted in each subset
Data retrospectively accrued 426 patients
Data prospectively accrued 1109 patients (72%)
Median follow-up 3.5+ years, range 1–8+ years
a7 patients had both diseases
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includes information on 623 patients with mM and 919 pa-
tients with mRCC (7 patients had both diseases). These re-
ports were queried for the development of irAEs. All
reported AEs and SAEs were evaluated for potential irAEs,
in addition to those reported directly as irAEs. AEs, SAEs,
and irAEs were not audited, and reporting was a function
of data entry at each participating site. Acute AEs and SAEs
related to IL-2 administration which resolved after treat-
ment were considered secondary to capillary leak syndrome
or secondary cytokine effects, and consistent with standard
management and assessments noted in previous reports
[20–22, 35–38].
The emphasis of PROCLAIMSM is collection of data
related to IL-2 treatment, however some reports in-
cluded irAEs related to additional CPI treatment (not
universally capturing all of these). IrAEs were catego-
rized as occurring before, during or after IL-2 adminis-
tration, and evaluated for relationship to IL-2 and/or to
CPI administration. Median follow-up for the entire
1535 patients was 3.5+ years (range 1–8+ years).
Statistical analysis
Overall response rate (ORR), complete + partial re-
sponse (CR + PR) as well as tumor control (TC), CR +
PR + stable disease (CR + PR + SD) was compared be-
tween all patients reported to have irAEs versus those
with no irAE, using Fisher’s exact test. This was evalu-
ated overall, and evaluated based on disease type. Over-
all survival (OS) of mM and mRCC patients was
analyzed by disease type. OS curves were estimated by
Kaplan-Meier method, and comparison was made be-
tween those with no-irAE or irAE occurring before IL-2
(group I) versus those with irAE occurring during or
after IL-2 administration (group II), and significance was
analyzed by the Log-rank test. Additional OS curves
were constructed, limited to patients with irAEs related
to IL-2 only, excluding those attributed to CPI.
Results
One hundred fifty-two irAEs were reported in 130 pa-
tients (8.4% of all PROCLAIMSM patients). This in-
cluded 68% males and 32% females, with a median age
of 55.5 years (range 24–75 years). Ninety-nine irAEs oc-
curred in patients with mM (16% of mM patients), and
53 irAEs occurred in patients with mRCC (5.8% of
mRCC patients). Thirty-one irAEs occurred in patients
prior to their receiving IL-2 treatment, and some were
attributed to prior therapy, such as adjuvant interferon.
Twenty-four irAEs occurred during treatment with IL-2,
and 97 irAEs developed after completion of IL-2 treat-
ment. Seventy-four irAEs were attributed to IL-2 (occur-
ring during or after IL-2). Twenty-four irAEs occurred
after IL-2 and after subsequent CPI, and were attributed
to CPI. With another 15 irAEs, the cause could not be
distinguished between IL-2 or CPI (Table 2).
We evaluated the median number of IL-2 doses re-
ceived related to the development and timing of irAEs.
The median number of doses for those with no irAEs
was 19; for those with irAEs during IL-2 treatment
(could be between courses, but total doses were
counted) the median number of doses was 25, and for
those who developed an irAE after IL-2, the median
number of doses was 25. Therefore, there was no appar-
ent dose-irAE relationship.
Immune-related events (Table 3)
These data from PROCLAIMSM confirm that the major-
ity of IL-2 related irAEs were primarily vitiligo (all in pa-
tients with mM) and thyroid dysfunction (greater
incidence in mRCC patients than mM patients) com-
prising 70% of irAEs attributed to IL-2, and with limited
further impact on well-being. Less than 5% of limited
irAEs related to IL-2 alone required intervention (i.e.
holding IL-2), and these included joint pain, neuropathy,
hepatitis. Serious irAEs related to IL-2 were reported
and described below. Of note, in the PROCLAIMSM data
base, reporting of specific end-organ antibodies was not
requested.
Additional irAEs were reported and associated with
subsequent CPI treatment, but not all CPI treatment or
CPI-related irAEs were captured within the PRO-
CLAIMSM data base. Examples of irAEs reported and at-
tributed to CPI include auto-immune hemolytic anemia,
vitiligo, psoriasis, colitis, hepatitis, thyroid dysfunction,
Table 2 Timing of Immune-Related Adverse Events with Relation to IL-2 Treatment
irAEs/Total Patients (%) Prior to IL-2 During IL-2 After IL-2
Total 152/1535 (8.4%) 31 24 97
mM 99/623 (16%) 16 12 71
mRCC 53/920 (5.8%) 15 12 26
Total irAEs 31 24 97
Related to IL-2 NA During and after IL-2 74
Undetermined if Related to IL2 or CPI NA 15
Related to CPI NA 24
mM metastatic melanoma, mRCC metastatic renal cell cancer, irAEs immune-related adverse events, IL-2 interleukin-2, CPI checkpoint inhibitor, NA - not applicable
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uveitis, encephalopathy, adrenal insufficiency and hypo-
physitis. These data from PROCLAIMSM confirm the
frequent serious nature of irAEs related to CPI adminis-
tration, often requiring acute intervention and possibly
chronic management (52% of CPI irAEs – hypophysitis,
colitis, hepatitis, uveitis).
Serious immune-related events (Table 3)
Among patients experiencing irAEs and reported to the
PROCLAIMSM registry, there were 15 serious irAEs re-
ported in 14 patients. Nine were in patients with mM
and 6 were in patients with mRCC. Among the mRCC
patients, all 6 serious irAEs occurred during IL-2 admin-
istration. Among the mM patients, 4 events were during
IL-2 administration, and 5 were after IL-2. Of note,
myocarditis was reported in 9 patients, all occurring
during IL-2 administration and requiring termination of
IL-2 therapy. This diagnosis was evaluated in all cases
based on enzyme release (laboratory evaluation), and in
7, there were no clinical, ECG, or echocardiogram find-
ings, consistent with IL-2-mediated myocarditis. In one
case, there were abnormal ECG and echocardiogram
findings and clinical symptoms, and in one case there
were asymptomatic ventricular arrhythmias. All cases re-
solved, and there were no chronic effects noted. Two
additional serious irAEs attributed to IL-2 were the de-
velopment of myasthenia gravis in one patient and
Guillain-Barre syndrome in one patient. Four additional
serious irAEs reported in PROCLAIMSM were attributed
to subsequent CPI therapy, and include one each of col-
itis, encephalopathy, neuropathy, and uveitis.
Response evaluation (Tables 4 and 5)
We evaluated best overall response (OR = CR + PR) and
the achievement of tumor control (TC = CR + PR + SD)
among all patients with irAEs, irrespective of timing of
occurrence versus those with no irAEs. When evaluated
overall, OR was observed in 34.5% of patients with irAEs
and 21.8% of those with no irAEs, a significant differ-
ences in OR (p = 0.0014). TC was observed in 71% of pa-
tients experiencing irAEs compared with 56% of those
who did not experience irAEs, a significant difference in
tumor control (p = 0.0008).
We also evaluated TC and OR by disease type, among
those with irAEs versus those with no irAEs. In patients
with mM, OR was 38.1% in those with irAE and 20.8% in
those with no irAE (p = 0.0058). TC was 72.6% in those
with irAE and 51.8% in those with no irAE (p = 0.0013). In
contrast, in patients with mRCC, OR was 28.3% in those
with irAE and 22.6% in those with no irAE (p = 0.5999)
and TC was 69.6% in those with irAE compared with
58.9% in those with no irAE (p = 0.6263), Thus, the signifi-
cant difference observed in response and tumor control
correlating with immune events is driven by the signifi-
cant effect in patients with melanoma, although the num-
bers of mRCC patients is smaller.
Overall survival
OS was significantly greater among those experiencing
irAEs during or after IL-2 treatment (Group II), com-
pared with those with no irAEs or irAEs reported prior
to IL-2 treatment (Group I). Among patients with mM,
those experiencing irAE during/after IL-2 had a median
survival of 48 months compared with 18 months for
Table 3 Immune Related Adverse Events (irAEs) and Serious
irAEs Reported
IrAEs related to Interleukin-2
1. 70% low level requiring no to minimal intervention
a. Vitiligo in mM patients
b. Thyroid dysfunction: 3 times more common in mRCC than mM
2. <5% irAEs reported requiring intervention (holding IL-2)
a. joint pain
b. Neuropathy
c. Hepatitis by enzyme elevation
15 Serious irAEs reported in overall Data Base among 152 irAEsa
6 in patients with mRCC – all during IL-2
9 in mM patients – 4 during IL-2; 5 after IL-2
9 patients - Myocarditis – all during IL-2
7 patients, only enzyme release; no clinical, electrocardiogram or
echocardiogram findings
2 patients – elevated enzymes; 1- abnormal electrocardiogram and
symptoms; 1 – elevated enzymes and asymptomatic ventricular
arrhythmia.
1 patient each - Myasthenia Gravis, Guillain Barre - both related to IL-2
4 serious irAEs reported related to CPIa: 1 each: colitis, encephalopathy,
neuropathy, uveitis
airAEs related to CPI were not required to be reported
Table 4 Tumor Response by Immune-Related Adverse Event
Occurrence
Best Responsea irAE, n = 130 pts No irAE, n = 1405 pts
Complete Response (CR) 8 (6.2%) 67 (4.8%)
Partial Response (PR) 37 (28.5%) 239 (17%)
Stable Disease (SD) 48 (37%) 483 (34.4%)
Progressive Disease 32 (25%) 470 (33.5%)
Missing 5 (3.8%) 146 (10.4%)
CR + PR + SD (n, %) 93 (71%) 789 (56%)
bp = 0.0008
CR + PR (n, %) 45 (34.6%) 306 (21.8%)
cp = 0.0014
irAE immune-related adverse event; pts.-patients;
aBest response is determined from responses captured between baseline IL-2
administration and prior to subsequent treatment
bFisher’s exact test comparing CR + PR + SD by irAE to no irAE
cFisher’s exact test comparing best response by irAE to no irAE
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those with no or prior irAE (p < 0.0001), (Fig. 1a).
Among patients with mRCC, those experiencing irAE
during/after IL-2 had a median survival of 60 months
compared with 40 months for those with no or prior
irAE (p = 0.0302), (Fig. 2a). Subsequent analysis removed
subjects whose irAEs were attributed to CPIs, and the
OS curves remain statistically significantly greater for
those experiencing irAEs during/after IL-2 and attrib-
uted to IL-2. (Figs. 1b, 2b).
Discussion
Immunotherapy for cancer has long been associated
with immune related adverse events (irAEs) affecting
non-tumor target tissues [1–7]. The most frequently af-
fected organ reported is the thyroid gland, with both
hypo- and hyper dysfunction described. Other frequent
end-organ targets are liver and skin, and also reactiva-
tion of prior autoimmune conditions, such as colitis,
psoriasis, and rheumatoid arthritis. Although there is de-
bate regarding the relationship of irAEs with respect to
improved clinical outcome [4, 7, 9, 10, 12, 14], more re-
cent data support this relationship [14, 33]. In this
report, we have provided a contemporary evaluation of
the relationship between IL-2 -related irAEs and clinical
outcome of patients with mM and mRCC following high
dose IL-2 treatment.
The PROCLAIMSM data base provides largely pro-
spectively accrued data on patients treated with high
dose IL-2, and provides information on treatment
course, toxicity, clinical outcome and potential long-
term toxicity. Additionally, in this era of multiple new
treatments, it provides an initial snapshot of outcome of
sequential therapies for patients with mM and mRCC,
and in some cases, sequential toxicities, based on the
different treatments employed. This study however, may
be limited by the lack of consistent reporting of low
grade irAEs from either IL-2 or CPI, as well as no re-
quirement for reporting of CPI use and subsequent
emergence of CPI-related irAEs in these patients.
The majority of irAEs related to IL-2 therapy are low-
grade, involving thyroid and skin, and not requiring
major intervention or change in therapy [1–9, 14]. How-
ever, serious irAEs may occur and careful monitoring of
patients receiving high dose IL-2 is always warranted,
Table 5 Response by irAE and Disease Type
Best Response mM mRCC
irAE, n = 84 No irAE, n = 539 irAE, n = 46 No irAE, n = 873
Complete Response (CR) 5(6.0%) 23(4.3%) 3 (6.5%) 44(5.0%)
Partial Response (PR) 27 (32.1%) 89 (16.5%) 10 (21.7%) 153 (17.5%)
Stable Disease (SD) 29 (34.5%) 167 (31.0%) 19 (41.3%) 317 (36.3%)
Progressive Disease (PD) 19 (22.6%) 211 (39.1%) 13 (28.3%) 262 (30.0%)
Missing 4 (4.8%) 49 (9.1%) 1 (2.2%) 97 (11.1%)
CR + PR (n,%) 32 (38.1%) 112 (20.8%)
aP = 0.0058
13 (28.3%) 197 (22.6%)
aP = 0.5999
CR + PR+ SD (n, %) 61 (72.6%) 279 (51.8%)
bP = 0.0013
32 (69.6%) 514 (58.9%)
bP = 0.6263
aFisher’s exact test comparing best response by irAE
bFisher’s exact test comparing tumor control by irAE
Fig. 1 a: Overall Survival for Melanoma Patients with or without Immune-Related Adverse Events, Comparing Group I (no irAE/or irAE before IL-2) with
Group II (irAE During/After IL-2). (Autoimmune Disease = irAE), p < 0.0001. b: Overall Survival in Patients with mM, comparing Group I with Group II,
removing those with irAEs due to CPI. (Autoimmune Disease = irAE), p < 0.0001
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for both the acute toxicity of the treatment, and the po-
tential for serious irAEs such as myocarditis and neuro-
logic events [16, 18, 19]. Nevertheless, the vast majority
of patients treated with high dose IL-2 have no long-
term sequelae once treatment is complete. In the pub-
lished literature, there is reported a broader spectrum
and often greater intensity of irAEs noted in patients
treated with CPI therapy [23, 33, 39]. Of note is the ob-
servation in patients treated with sequential immuno-
therapies, that there is not always recapitulation of the
same toxicities (personal communications). It is hypoth-
esized that differences in activation of T-cell responses
and subsets are reflected in the different spectrum of
irAEs observed among different classes of immunother-
apy agents.
In this contemporary report of irAEs associated with
high dose IL-2 treatment, the following observations have
been made: [1] Overall, patients developing IL-2 related
irAEs have significantly improved response (CR + PR) and
tumor control (CR + PR + SD) compared to those who did
not develop irAEs (Table 4). However, when analyzed by
tumor type, this actually reflects a greater impact on re-
sponse and tumor control in the melanoma patients ex-
periencing irAEs, albeit the number of renal patients is
smaller than the number of melanoma patients (Table 5).
[2] The development of IL-2-related irAEs is associated
with significantly improved overall survival in both mM
and mRCC patients, when analyzed individually, com-
pared to those with no irAEs (Figs. 1a and 2a), and exclud-
ing those with CPI-associated irAEs (Figs. 1b and 2b).
These findings continue to support the association of im-
mune activation from immunotherapy with better patient
outcome. Of interest is the differential effect in mRCC,
with a survival benefit, despite similar response rates in
those with irAE and no irAE. This could be a factor of the
smaller numbers, or in fact, to differences in effect on the
disease itself. This may be relevant as immunotherapy ex-
pands into other disease entities.
These findings, and those reported with respect to
CPIs also suggest new considerations as clinical trials
move further into the study of combination immuno-
therapy for cancer. The combination of anti-CTLA-4
plus anti-PD-1 checkpoint inhibitors in patients with
mM has demonstrated a higher response rate compared
to single agent anti-CTLA-4, and an increase in grade 3/
4 irAE rate [40–43].
However, a different combination reported by
Prieto et al. of 3 phase II studies, two with the com-
bination of anti-CTLA-4 and peptide vaccine and
one with the combination of anti-CTLA-4 and high
dose IL-2 in patients with advanced melanoma dem-
onstrated combinability in terms of toxicity [44]. In
the long-term follow-up of these studies, it is not-
able that the combination of anti-CTLA-4 with IL-2
demonstrated a doubling of complete response rate
compared to the CR rate in the two studies with
anti-CTLA-4 and peptide vaccine (17% vs 6%, 7%), and of
the 15 CR patients, 14 were ongoing at the time of the re-
port at 54+ to 99+ months [44]. Additionally, the median
survival for the 3 regimens was greatest in those receiving
anti-CTLA-4 with IL-2 (16 months vs 14 and 13 months)
and the 5-year survival was 25% in the group with
anti-CTLA-4 and IL-2. Of considerable interest was a
reduced incidence of grade 3/4 irAEs among the pa-
tients receiving anti-CTLA-4 plus IL-2 compared to
those in the two protocols receiving anti-CTLA-4
plus peptide vaccine (17% vs 29%, 32%). The authors
postulate that IL-2-related induction of regulatory T-cells
in addition to cytotoxic T-cells may decrease the activity
of auto-reactive T-cells that may lead to serious irAEs and
thus improve the therapeutic ratio [44]. This clearly needs
further investigation.
The addition of activated tumor-infiltrating lympho-
cytes (TILs) in combination with IL-2, initially studied
in advanced melanoma, but now in multiple tumor
types, continues to be investigated. These approaches
Fig. 2 a: Overall Survival for mRCC Patients with or without Immune-Related Adverse Events, Comparing Group I (no irAE/or irAE before IL-2) with
Group II (irAE During/After IL-2) (Autoimmune Disease = irAE), p = 0.0302. b: Overall Survival in Patients with mRCC, comparing Group I with
Group II, removing those with irAE due to CPI. (Autoimmune Disease = irAE), p = 0.0302
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utilize shorter courses of high dose IL-2 or different
dose/schedules of IL-2 [45, 46]. Single institution studies
report greater responses and apparent improved survival
[45, 46]. Historical series have only reported acute toxic-
ities, and not irAEs. Numerous trials are ongoing, in-
cluding multicenter trials, with central production of
TILs, as well others exploring differing doses of IL-2,
and combinations of IL-2, TILs and CPIs. The occur-
rence of irAEs, either early or late should be compiled.
Another approach to enhancing the immunotherapeu-
tic effect of IL-2 involves the combination of localized
radiation (producing tumor antigen release) followed by
high dose IL-2. A recent publication by Hannan et al.
has demonstrated the potential for synergy from this ap-
proach in patients with mRCC [47]. In this single insti-
tution report, there appeared to be enhanced clinical
activity and follow-up is ongoing. Of interest would be
the level of low grade versus high grade irAEs with this
approach. The investigators do not note unexpected tox-
icity (Hannan, personal communication) Others are ex-
ploring this combination also, among patients with both
mM and mRCC.
Considering the recent evaluation of the combination
of anti-CTLA4 plus anti-PD1 in mM and the similarity
in outcome with anti-PD1 alone, as well as the less se-
vere irAE profile with anti- PD1, this agent may in fact
be a clinically very feasible agent to combine with IL-2.
Studies are ongoing. The results from the Prieto, et al.
report support that serious irAEs from the combination
of a checkpoint inhibitor (anti-CTLA-4) and IL-2 will
not a priori be additive, and in fact might be less, and
manageable with such combinations [44]. They did not
report irAEs of less than grade 3 severity, which in our
series reflect 70% of IL-2 related irAEs. A recent review of
the newer immunotherapies is entitled “autoimmune
events - the Achilles’ heel of immunotherapy” [39], but it
is also possible that different combinations will lead to dif-
ferent spectra of toxicity, with the potential for enhanced
durable response and survival and lower grade irAEs.
The advantages of an immunotherapeutic agent such as
high dose IL-2 for consideration in combination therapy
are the following: a) the short course of therapy, b) the
extensive experience with its administration, c) the very
limited extent of long-term irAE complications and import-
antly, d) the documented long-term disease-free survivor-
ship demonstrated over many decades [44, 48–54].
Therefore, attempts to enhance antigen presentation, or se-
lective cytotoxic T-cell activation, or ex vivo T-cell activa-
tion, among other approaches, should capitalize on this
investigation of combined immunotherapy.
Conclusions
In summary, the irAE profile observed with high dose
IL-2 in this registry study demonstrates generally
manageable events, and rare long-term toxicity. There
does appear to be a correlation between irAE develop-
ment and improved response (mM) and survival (mM
and mRCC) following treatment with high dose IL-2.
High dose IL-2 is a short, manageable treatment course
that may be combinable with the newer CPI agents and
other developing immunotherapies, and these combina-
tions will not necessarily lead to additive irAEs and tox-
icity. Obviously, the ultimate goal is to enhance response
rate, tumor control and overall survival.
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